

## Background

The global pharmaceutical industry is regarded as one of the most resilient sectors, largely unaffected by economic fluctuations. This vast industry encompasses branded and generic products, finished dosage formulations, and over-the-counter (OTC) medicines. Historically, the pharmaceutical market has been dominated by the United States, Western Europe, and Asia-Pacific countries. The primary growth drivers have been the developed markets, particularly the USA, United Kingdom, the leading European countries (France, Germany, Italy and Spain), and Japan. In the coming five years, emerging pharmaceutical markets are expected to significantly contribute to the industry's growth.

Several factors contributed to the growth of the domestic market. There was a significant increase in demand in both acute and chronic segments. The introduction of new products also drove growth. Therapies for cardiac conditions, diabetes, and central nervous system (CNS) disorders experienced lower double-digit growth, with other therapeutic areas also performing strongly.

Pharmaceutical companies are encountering various challenges that are altering their business dynamics. A critical issue in the current scenario is the drug regulatory system and regulatory legislation, both domestically and in global markets. For long-term sustainable growth, the industry must enhance domestic manufacturing of bulk drugs, intermediates, and key starting materials (KSM) while gradually reducing its dependence on imports from specific countries or regions.

## Rating Methodology

CARE Ratings South Africa (Pty) Limited has a detailed methodology for rating companies belonging to the manufacturing sector. CARE SA's rating process begins with the evaluation of the economy/industry in which the company operates, followed by the assessment of the business risk factors specific to the company. This is followed by an assessment of the financial and project-related risk factors as well as the quality of the management. This methodology is followed while analysing all the industries that come under the purview of the manufacturing sector. However, considering the size and diversity of the manufacturing sector, CARE SA has developed methodologies specific to various industries within the sector. These methodologies attempt to bring out factors, over and above those mentioned in the broad methodology, which is considered while analysing companies belonging to an industry.

CARE SA considers the following factors as critical determinants of credit risk associated with pharmaceutical companies.

1. Business/ Operational Risk: Business segment and product portfolio, geographical diversification in terms of presence in the regulated and semi-regulated markets, R&D focus, regulatory and legal compliances (both domestic and exports)
2. Financial position
3. Project-specific challenges
4. Environmental, social and governance (ESG) risk factors

## 1. Business/ Operations Risk

### 1.1 Business Segment and Product Portfolio

Based on the business segment, the companies are broadly classified into bulk drug / Active Pharmaceutical Ingredients (APIs) manufacturing companies, formulation manufacturing companies or companies having integrated operation, i.e., engaged in the manufacturing of APIs and formulations as well as in contract manufacturing. Bulk drugs are APIs used to manufacture formulations.

**Therapeutic segments:** CARE SA looks into the therapeutic segmentation of products, viz, Acute or Chronic. The acute therapeutic segment (like anti-infective and pain management) constitutes a major share of pharmaceutical sales in the domestic market as well as exports in less-regulated markets. On the other hand, the chronic therapeutic segments (like cardiovascular, oncology, diabetes and anti-depressants) command a major share in the regulated markets. Companies having products largely in the chronic segment are viewed favourably as these products provide long-term sustainability to their revenue visibility. Furthermore, while analysing a company based on therapeutic segment, CARE SA looks into the details regarding the company's presence in different therapeutic segments, percentage of the company's revenue from top therapeutic segments, market share in the particular therapeutic segment, degree of criticality of the top therapeutic segments and past track record and future strategy of the company to diversify or broaden its therapeutic presence.

**Product portfolio:** CARE SA also analyses the product portfolio of the pharmaceutical company i.e., the total number of products in the portfolio, percentage of the total revenue from the top 10 products, diversity of products in terms of dosage form, past track record of the company in developing and adding new products in product portfolio and pipeline of products for future growth prospects. CARE SA analyses the year-on-year growth rate of existing products in terms of value as well as volume which indicates the product's life cycle. In addition to it, CARE SA analyses the expected launch of new products during the year, the market size of those products and expected revenue growth from new products. A company's ability to produce speciality or complex products, such as injectable, topical drugs, and biosimilars are also viewed favourably.

Therapeutic-wise and product-wise analysis help in better understanding the sustainability of revenue and profitability going forward.

**Formulation companies:** Additionally, while analysing formulation companies, it is important to assess their market positioning by understanding the company's market share in the particular therapeutic segment as well as diversification in the product portfolio. This enables the assessment of the stability or sustainability of its future growth. Moreover, CARE SA considers the marketing and distribution setup of the company which plays a key role in assessing the market penetration and future growth prospects of the company. The formulation companies can be classified into patented, branded generic and generic formulations. African Pharmaceutical companies in general have a large presence in branded generic and generic business. CARE SA looks favourably at companies having branded generic formulations as they command higher margins with better market positioning in particular therapeutic segments in light of low entry barriers. Moreover, to assess the operating efficiency of the formulation companies, CARE SA analyses the gross margin and productivity of its sales forces.

**Bulk drug/ API companies:** The bulk drug/API companies are relatively capital intensive & fragmented with threats from cheaper imports; CARE SA also analyses the cost efficiency, technical upgradation of plant, manufacturing capabilities, third-party tie-ups, customer base and its diversification, product concentration, etc. CARE SA analyses the revenue from top products and customers to arrive at concentration risk. Over-dependence for the raw material on a particular country or few suppliers can create significant supplier concentration risk for the company. The south African pharma companies are heavily dependent on China for their raw material requirement i.e., KSM and Bulk drug/ API. Diversification in supplier base across geographies is viewed favourably by CARE SA.

## 1.2 Geographical Diversification

The revenue of South African pharmaceutical companies is derived from domestic sales or export sales. The companies with diversified revenue streams, i.e., exports to different markets, are considered favourably as they provide more opportunity for growth as well as mitigate the risk related to any change in the regulation in any market.

Based on export markets, pharmaceutical companies can be broadly divided into those that export to regulated markets or those that export to semi-regulated markets. Both these markets have different dynamics in terms of regulation, competition, quality, manufacturing standards, patents, etc. Regulated markets are those where regulations are more stringent, while less-regulated markets have less-stringent regulations. There is a trade-off between the risk and return as far as exports to a regulated market or a semi-regulated market are considered.

For exports to the regulated market, the companies are required to follow more stringent regulation compliances related to patent and drug laws of those countries. Moreover, the regulated market offers pharmaceutical companies a huge opportunity to grow in the generic segment on the back of patent expirations scheduled in the coming years. To analyse the company's strength and presence in a regulated market, CARE SA takes into cognizance receipt of regulatory approvals from various regulatory authorities of respective nations. Approvals from regulatory authorities not only allow these companies to tap the generic opportunity but also open up opportunity in the Contract Research and Manufacturing Services (CRAMS) business. Furthermore, for companies pursuing the generic opportunity in the regulated markets, CARE SA looks at the number of ANDA (Abbreviated New Drugs Application) and approvals received. Apart from several ANDAs, CARE SA also analyses the quality of a company's product pipeline.

## 1.3 Research and Development (R&D) Focus

In the current scenario, with increasing competition in the domestic as well as global markets and changing business dynamics of pharmaceutical sector, there is a need for companies to focus more on R&D. This plays a significant role in the diversification of therapeutic segments/ product portfolios with improvement in the quality of products which is important for sustainable growth, in the long run, to achieve overall business strategies concerning products and markets.

CARE SA looks at the trend in R&D expenditure as a percentage of sales and compares the same with industry averages as well as comparable peers. CARE SA also looks into the past track record of the

company's capability to develop new molecules or to develop new dosage forms/ new drug delivery systems or develop a new combination of drugs, etc. Knowing the R&D budget as a percentage of sales helps understand if the company is creating a strong pipeline of future growth. It is observed that in the last few of years pharmaceutical companies have increased their R&D expenses to establish niche, complex and speciality product portfolios for the future and sustain the market position in a competitive business scenario.

R&D for domestic and less regulated markets: For these markets, the focus is on the development of a new combination of existing formulations as well as developing formulations for new therapy classes and APIs. South African pharmaceutical companies have grown consistently by launching new products in the domestic market and responding to the changing demand.

R&D for the regulated market: Higher investment is required in R&D for supporting the company's presence in the regulated markets. For companies following the generic strategy, the key focus area includes research for ANDAs, Drug Master Files (DMFs) and other such regulatory filings. CARE SA in its analysis assesses the product development capability of the entity across various therapeutic segments and its focus areas on the recent off-patent drugs, combination of products, etc.

For companies offering Contract Research And Manufacturing Services (CRAMS), R&D is focused on process research, synthetic chemistry and other services that they offer to global pharma companies for partnering with them for early-stage drug discovery and developments.

At the apex of the R&D pyramid, is research about New Chemical Entity (NCE) and Novel Drug Delivery System (NDDS). This involves the development of a novel drug which is a likely candidate for being granted a patent and becoming a blockbuster drug. This also may entail the development of a novel delivery system for an existing drug. Since new drug development activity is characterised by huge costs and low success rates, it is viewed carefully. The companies having relatively higher R&D spend are generally expected to provide greater sustainability to business operations.

#### **1.4 Manufacturing facilities and regulatory and legal compliances**

In the current scenario, regulatory and legal compliance is one of the larger challenges for pharmaceutical companies operating in domestic as well as in export markets. The regulatory aspect is extremely crucial given the rapid changes at the global level, largely concerning good manufacturing practices (GMP), good clinical practices (GCP) and good laboratory practices (GLP).

Part of the rating exercise involves assessing the performance track record on inspections carried out at the manufacturing facilities by various regulatory authorities of respective countries. Furthermore, post such inspections, the observations, if any, made by the regulatory authorities along with the company's response and remedial measures taken by it are evaluated. CARE SA analyses the instances of any product recall in the past, as well as any instances of ban or import alert for any of the manufacturing facilities of the companies by any regulators and the company's response to the same.

CARE SA also evaluates the revenue share contributed by a specific manufacturing facility and the products affected due to failure in observing the regulatory compliances and carries out the sensitivity analysis accordingly. Since the legal cost of any such litigation and the time for re-inspection is high, the revenue and profitability of the companies may be impacted; hence, the trigger of such regulatory-concerned events are critical from the credit perspective. Companies having multiple manufacturing plants/facilities with each plant having regulatory approvals, and capability to manufacture a variety of products is generally viewed favourably. Companies having only a single manufacturing facility carry a risk of asset concentration. Force majeure incidents, warning letters, import alerts, labour unrest, etc., may disrupt the company's operation significantly.

CARE SA looks at the extent of price control on the domestic product portfolio of the company vis-à-vis its impact on profitability. The phenomenon to bring down the prices of generics formulations through various price control measures is also observed in the developed markets. Further in the prominent developed markets, it is witnessed that the consolidation of the supply chain in the hands of a few large distributors also puts pressure on product pricing.

The companies having ANDA filing under Para – IV are subject to significant litigation risk as they look to invalidate the innovator company's existing patent before its expiration. For CRAMS players, non-compliance with manufacturing processes and drug quality can lead to termination of supply contracts and regulatory authorities imposing other penalties.

For API manufacturing companies, non-compliance with respect to the laid-down environmental and pollution control norms could attract action from the concerned regulatory authorities which may even lead to shutting down of their units. The risk is relatively high in the case of small and mid-size API manufacturing companies compared to organised companies that generally make the necessary investment in pollution control infrastructure such as zero liquid discharge facility. It is observed that the changes in environmental rules in major economies have led to disruption in production and increased the cost of raw materials for pharma companies. Hence, companies having a vertically integrated operation with relatively low reliance on imports have provided greater operating flexibility and sustained profitability.

## **2. Financial Risk**

CARE SA follows its standard ratio analysis methodology for manufacturing companies to assess the financial risk of companies in the pharmaceutical sector. Refer to CARE SA's Rating Methodology for 'Financial Ratio - Non-Financial Sector' which is available on the website [www.careedgesouthafrica.com](http://www.careedgesouthafrica.com).

## **3. Project-specific Risk**

For pharmaceutical companies, the nature of capital expenditure would be driven by the strategic decision pertaining to products and the market that the company wants to cater to.

In the recent past, many pharmaceutical companies have acquired overseas assets for expanding their product/ market reach and gaining access to the intellectual property of such companies. CARE SA looks at the realisation of the envisaged benefit and the extent of debt funding used for such acquisition.

For capital expenditure pertaining to setting up of a new manufacturing facility, necessary regulatory approvals are required. If the facility is being set up for catering to the regulated markets, any delay in receiving the approvals can delay the project which in turn can exert pressure on its cash flows especially if such project is significantly debt funded.

CARE SA also analyses the size of the ongoing/ proposed project in proportion to its net worth, past track record of handling & executing a similar size the project, means of finance (debt: equity ratio of the project), status of financial closure, impact on future financial performance post consideration of project risk as well as risk of time & cost overrun in the project among others.

#### **4. Environmental, social and governance (ESG) risk factors**

CARE SA in its overall credit rating framework directly or indirectly analyses the critical ESG risks and their impact on the credit profile of the entities. CARE SA analyses the materiality of ESG risk factors and mitigating factors, if any, being implemented by the entity.

**Environmental Risks:** Pharmaceutical entities do not face major environmental-related risk except for the entities engaged in API business. These entities are required to follow stringent pollution control norms set by the regulatory authorities on account of gas emission, water use and waste generation. Any violation in compliance with pollution control norms or strengthening of these norms would adversely impact operations. The entities which are gradually investing/ upgrading their auxiliary infrastructure to reduce carbon footprint, air/ water pollution and hazardous waste as well as efficiently use the natural/scarcе resources, would be viewed favourably.

**Social Risks:** Pharmaceutical entities face a high social risk related to the safety of the consumers. CARE SA analyses the regulatory audit track record and instances of litigations and product-recall apart from quality of manpower to assess the social risk. The pharmaceutical sector is exposed to reputation risk related to the quality of the product/ services. Further, compliance with the various labour laws, adequate safety for workers, ensuring customer privacy and fair marketing practices provide long-term sustainability.

**Governance Risks:** CARE SA looks at the composition of the board of directors and track record of legal and statutory compliance by its management/ directors to understand the corporate governance structure. Further, the quality of disclosure related to financial statements, related party transactions and transparency in sharing information with various stakeholders are also helpful to gauge the corporate governance practices.

#### **Conclusion**

The overall credit risk profile of companies in the pharmaceutical sector is driven by their relative position in the domestic as well as export markets, geographical diversification and presence across therapeutic segments, their product portfolio, and the ability to handle the regulatory challenges and its focus on R&D.

CARE SA analyses each of the above factors to arrive at the overall assessment of the credit quality of the Issuer. Credit rating is a futuristic assessment, and the rating outcome is ultimately an assessment of the fundamentals and the probabilities of change in the fundamentals in future. Moreover, for arriving at the rating outcome, CARE SA also considers future estimation of the company's financials based on past trends and future strategies, competition, industry trends, economic conditions, and other considerations.

**[Reviewed in December 2025. Next Review due in December 2026]**



## Contact

|                      |                                    |                                         |                             |
|----------------------|------------------------------------|-----------------------------------------|-----------------------------|
| Saurav Chatterjee    | Director & Chief Executive Officer | saurav.chatterjee@careratingsafrica.com | + 230 5862 6551 / 5955 3060 |
| Vidhyasagar Lingesan | Chief Rating Officer               | vidhya.sagar@careratingsafrica.com      | + 230 5273 1406 / 5955 3060 |
| Mradul Mishra        | Media Relations                    | mradul.mishra@careedge.in               | +91 - 22 - 6754 3596        |

## Care Ratings South Africa (PTY) Limited

Registered Address: 1<sup>st</sup> Floor, 35 Ferguson Road, Illovo, Sandton, 2196, Johannesburg, South Africa

Business Address: Spaces Atrium on 5<sup>th</sup>, 9<sup>th</sup> Floor, 5<sup>th</sup> Street, Sandton, 2196, Johannesburg, South Africa

FSC License No.: CRA007

## About Us:

CARE Ratings South Africa (Pty) Limited (CareEdge South Africa) is incorporated in 2023 to provide credit ratings and related services in South Africa. CARE SA is a wholly owned subsidiary of CARE Ratings Africa (Private) Limited (CareEdge Africa), which is a part of CareEdge Group based in India. In October 2024, CareEdge South Africa has received its license from the Financial Sector Conduct Authority (FSCA) of South Africa. CARE SA provides Ratings of various instruments such as Bonds, Money Market Instruments, Bank Deposits, Structured Finance and Bank Facilities. CareEdge South Africa also does Issuer Rating (Banks, Corporates, NBDTIs & Insurance companies). Please visit CareEdge South Africa website - <https://www.careedgesouthafrica.com>.

About CareEdge Group

CARE Ratings Ltd. (CareEdge Ratings)

CareEdge Ratings, based out of India and the parent company of the CareEdge group, was incorporated in 1993 and is the one of the largest Credit Rating Agency (CRA) of India and features amongst the top ten credit rating agencies globally. Since inception, CareEdge Ratings has rated USD 2.5 trillion worth of debt and has undertaken over 95,000 rating assignments which includes ratings of large, mid and small corporates as also sub sovereign and state utility companies. Please visit CareEdge website - <https://www.careratings.com>.

CARE Ratings (Africa) Private Limited

In the quest of supporting the development of capital market in African Union, CareEdge Group has set up the first rating agency of Mauritius - CARE Ratings (Africa) Private Limited (CareEdge Africa) in 2014, which is licensed by Financial Services Commission of Mauritius and Capital Markets Authority of Kenya. CareEdge Africa is also recognised by the Bank of Mauritius as External Credit Assessment Institution (ECAI). CareEdge Africa's shareholders are CARE Ratings, India (CARE Ratings), African Development Bank (AfDB), MCB Equity Fund (MEF) and SBM (NFC) Holdings Limited (SNHL). Please visit CARE Ratings Africa website - <https://www.careratingsafrica.com>.

## Disclaimer for Rating Methodology

The rating methodology provided by CARE Ratings South Africa (Pty) Limited ("CARE SA") is intended to offer a comprehensive framework for assessing creditworthiness. The rating methodology is based on various quantitative and qualitative factors, and while it aims to provide a consistent and objective approach, it is not infallible.

CARE SA publishes its rating methodologies in its website at [https://www.careedgesouthafrica.com/criteria\\_methodologies](https://www.careedgesouthafrica.com/criteria_methodologies). Along with this, CARE SA publishes its various criteria and policies on code of conduct, conflict of interest, rating process, in our website and update the same from time to time.

This rating methodology has been made available on the website solely for informational purposes, and no part of this methodology should be used, copied, reproduced, distributed without the prior consent of CARE SA or without appropriate credit being given to CARE SA. This methodology, in whole or in part, shall not be modified, reverse engineered in any form and shall not be used for obtaining any commercial gains or for any unauthorised or unlawful purpose. No part of this methodology or report shall be construed as any accounting, legal, regulatory, tax, research, or investment advice.

Ratings are statements of opinion and not statements of fact. Ratings are opinions as on date they are issued and are subject to change based on new information or changes in the market environment. They do not constitute recommendations to buy, hold, or sell any securities or make any investment decisions. Ratings should not be the sole basis for any investment decision. Ratings are not substitutes for professional judgment in investment decisions, and users should rely on their own judgment and seek professional advice before making any financial decisions. All opinions expressed are in good faith, based on the information available at the time of the rating. These opinions are subject to change without notice. The methodology and resulting ratings are not solicitations to engage in any transaction with the entities rated. CARE SA does not act as a fiduciary, investment advisor or in the interest of the issuer or issuances it rates.

While CARE SA has obtained information from sources it believes to be reliable, CARE SA does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CARE SA is not liable for any errors or omissions in the methodology or for any actions taken based on the ratings. CARE SA does not guarantee the accuracy, completeness, or adequacy of the methodology or the resulting ratings. CARE SA and its associates disclaim all liability for any damages arising from the use of its methodology, reports or any rating actions. ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE DISCLAIMED. In no event shall CGIL or its affiliates be liable for any direct, indirect, incidental, punitive, or consequential damages arising from the use of the rating methodology or the ratings.

CARE SA may receive compensation for providing credit ratings from issuers or underwriters of securities or obligors. CARE SA reserves the right to disseminate its reports which may include its opinions, assessments, analysis or research on its websites, various CARE SA publications or third-party distributors. CARE SA maintains strict confidentiality of non-public information received during the rating process and has policies to maintain confidentiality of data it receives.

By using this rating methodology, you acknowledge and agree to these terms and conditions.

All rights reserved @ CARE Ratings South Africa (Pty) Limited